At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 14,752 enrolled
Drug / intervention
Exenatide Once Weekly +1 moredrug
Likely dose
Exenatide Once Weekly 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL). A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus.
In Brief
A Phase 3 clinical trial evaluating Exenatide Once Weekly and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 14,752 participants across 629 sites in 35 countries.
Detailed Summary
This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesArgentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Germany, Hong Kong, Hungary, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2010
Enrollment StartJun 2010
Primary CompletionApr 2017
Study CompletionApr 2017
TodayJul 2026
First PostedJun 15, 2010
Enrollment StartJun 18, 2010
Primary CompletionApr 21, 2017
Study CompletionApr 24, 2017
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 16.0 years ago
Interventions
Exenatide Once Weeklydrug
Subcutaneous injection, 2 mg, administered once weekly.
Placebodrug
Subcutaneous injection, matching volume of placebo, administered once weekly.